Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesAllos Therapeutics Announces FDA Advisory Committee Recommends Accelerated Approval of FOLOTYN(TM) for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma
Allos Therapeutics, 09/28/09
Allos Therapeutics, Inc. announced that the U.S. Food and Drug Administration's Oncologic Drugs Advisory Committee voted 10–4 that the response rate and duration of response observed with FOLOTYNTM are reasonably likely to predict clinical benefit in patients with relapsed or refractory peripheral T–cell lymphoma. PTCL comprises a biologically diverse group of aggressive blood cancers that has a worse prognosis than most other types of lymphoma, including B–cell lymphoma. If approved, FOLOTYN would be the first drug approved by the FDA for the treatment of relapsed or refractory PTCL.
Today in Drug Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
FDA Drug Approval Summary: Bevacizumab (Avastin) as Treatment of Recurrent Glioblastoma Multiforme
The Oncologist, 12/02/09
Ustekinumab (Stelara): First-in-class human monoclonal antibody approved for treatment of moderate-to-severe plaque psoriasis
Formulary , 12/02/09
Safety concerns slow new drug review and approval processes
Formulary , 12/02/09
Sponsor
Article Search
Sponsor